{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:27:38Z","timestamp":1794414458443,"version":"4.9.1"},"reference-count":180,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004281","name":"Narodowe Centrum Nauki","doi-asserted-by":"publisher","award":["UMO-2021\/41\/B\/NZ7\/00328"],"award-info":[{"award-number":["UMO-2021\/41\/B\/NZ7\/00328"]}],"id":[{"id":"10.13039\/501100004281","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.pharmthera.2026.109106","type":"journal-article","created":{"date-parts":[[2026,8,29]],"date-time":"2026-08-29T23:10:57Z","timestamp":1788045057000},"page":"109106","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Targeting glycine transporter type 1 (GlyT1) in epilepsy: Pathophysiological rationale and therapeutic perspectives"],"prefix":"10.1016","volume":"288","author":[{"given":"Nikola","family":"Gapi\u0144ska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u0142","family":"Abram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Jakubiec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Rafa\u0142o-Uli\u0144ska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernadeta","family":"Szewczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Kami\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Wla\u017a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katarzyna","family":"Soca\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2026.109106_bb0005","doi-asserted-by":"crossref","DOI":"10.3390\/ijms241411236","article-title":"Glycine: The smallest anti-inflammatory micronutrient","volume":"24","author":"Aguayo-Cer\u00f3n","year":"2023","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0010","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1600-0404.1988.tb03690.x","article-title":"Alteration of amino acid content of cerebrospinal fluid from patients with epilepsy","volume":"78","author":"Araki","year":"1988","journal-title":"Acta Neurologica Scandinavica"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0015","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1007\/s00429-013-0537-3","article-title":"GlyT1 and GlyT2 in brain astrocytes: Expression, distribution and function","volume":"219","author":"Aroeira","year":"2014","journal-title":"Brain Structure & Function"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0020","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3389\/fncel.2013.00184","article-title":"Glycine receptors and brain development","volume":"7","author":"Avila","year":"2013","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0025","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1002\/ana.20480","article-title":"Tumor necrosis factor-alpha inhibits seizures in mice via p75 receptors","volume":"57","author":"Balosso","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0030","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000503831","article-title":"The epidemiology of epilepsy","volume":"54","author":"Beghi","year":"2020","journal-title":"Neuroepidemiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0035","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1177\/09727531231185991","article-title":"Recent Progress in the development of new antiepileptic drugs with novel targets","volume":"30","author":"Belete","year":"2023","journal-title":"Annals of Neurosciences"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0040","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1042\/BST0340055","article-title":"Glycine transporters: Essential regulators of synaptic transmission","volume":"34","author":"Betz","year":"2006","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0045","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1189\/jlb.0306164","article-title":"DAMPs, PAMPs and alarmins: All we need to know about danger","volume":"81","author":"Bianchi","year":"2007","journal-title":"Journal of Leukocyte Biology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0050","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fnmol.2016.00026","article-title":"The biochemistry and epigenetics of epilepsy: Focus on adenosine and Glycine","volume":"9","author":"Boison","year":"2016","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0055","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1111\/j.1528-1167.2006.00502.x","article-title":"Imaging the neural substrates involved in the genesis of pentylenetetrazol-induced seizures","volume":"47","author":"Brevard","year":"2006","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0060","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1111\/j.1476-5381.2012.01975.x","article-title":"The solute carrier 6 family of transporters","volume":"167","author":"Br\u00f6er","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0065","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.biopsych.2016.11.014","article-title":"Bitopertin in negative symptoms of schizophrenia-results from the phase III FlashLyte and DayLyte studies","volume":"82","author":"Bugarski-Kirola","year":"2017","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0070","first-page":"1","article-title":"New standards for negative symptom assessment","volume":"42","author":"Carpenter","year":"2016","journal-title":"Schizophrenia Bulletin"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0075","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/hipo.22274","article-title":"Glycine N-methyltransferase expression in the hippocampus and its role in neurogenesis and cognitive performance","volume":"24","author":"Carrasco","year":"2014","journal-title":"Hippocampus"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0080","doi-asserted-by":"crossref","first-page":"2742","DOI":"10.1038\/npp.2014.4","article-title":"Relationship between glycine transporter 1 inhibition as measured with positron emission tomography and changes in cognitive performances in nonhuman primates","volume":"39","author":"Castner","year":"2014","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0085","doi-asserted-by":"crossref","DOI":"10.1007\/s00210-026-05276-y","article-title":"GlyT1 (SLC6A9) inhibition in neurological and psychiatric disorders","author":"Cavalcante","year":"2026","journal-title":"Naunyn-Schmiedebergs Archives of Pharmacology."},{"key":"10.1016\/j.pharmthera.2026.109106_bb0090","doi-asserted-by":"crossref","DOI":"10.1186\/s12868-026-00999-3","article-title":"Slc6a9 is distributed in glial cells and neurons across several nervous system regions, whereas Slc6a5 is more restricted to neurons in the caudal brain","volume":"27","author":"Ceder","year":"2026","journal-title":"BMC Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0095","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1113\/jphysiol.2014.271700","article-title":"Activation of glycine receptors modulates spontaneous epileptiform activity in the immature rat hippocampus","volume":"592","author":"Chen","year":"2014","journal-title":"Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0100","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuint.2023.105657","article-title":"Epigenetic regulation in epilepsy: A novel mechanism and therapeutic strategy for epilepsy","volume":"173","author":"Chen","year":"2024","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0105","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1080\/13543776.2018.1429408","article-title":"Glycine transporter-1 inhibitors: A patent review (2011-2016)","volume":"28","author":"Cioffi","year":"2018","journal-title":"Expert Opinion on Therapeutic Patents"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0110","doi-asserted-by":"crossref","first-page":"3404","DOI":"10.2174\/1568026616666160405113340","article-title":"Inhibitors of Glycine Transporter-1: Potential therapeutics for the treatment of CNS disorders","volume":"16","author":"Cioffi","year":"2016","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0115","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1016\/j.biopha.2018.03.048","article-title":"Participation of the IKK-\u03b1\/\u03b2 complex in the inhibition of the TNF-\u03b1\/NF-\u03baB pathway by glycine: Possible involvement of a membrane receptor specific to adipocytes","volume":"102","author":"Contreras-Nu\u00f1ez","year":"2018","journal-title":"Biomedicine and Pharmacotherapy"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0120","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1093\/cercor\/bhh147","article-title":"Localization of the GLYT1 glycine transporter at glutamatergic synapses in the rat brain","volume":"15","author":"Cubelos","year":"2005","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0125","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1111\/j.1471-4159.2005.03438.x","article-title":"The scaffolding protein PSD-95 interacts with the glycine transporter GLYT1 and impairs its internalization","volume":"95","author":"Cubelos","year":"2005","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0130","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.neuint.2013.09.002","article-title":"Localization of the glycine transporter GLYT1 in glutamatergic synaptic vesicles","volume":"73","author":"Cubelos","year":"2014","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41537-024-00499-5","article-title":"The dimensional structure of the positive and negative syndrome scale in first-episode schizophrenia spectrum disorders: An exploratory graph analysis from the OPTiMiSE trial","volume":"10","author":"Dal Santo","year":"2024","journal-title":"Schizophrenia (Heidelb)"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0140","first-page":"255","article-title":"Inbred mouse strains differ in their sensitivity to an antiseizure effect of MK-801","volume":"21","author":"Deutsch","year":"1998","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0145","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/01.WNF.0000236767.46526.1F","article-title":"Rare neurodevelopmental abnormalities of sarcosinemia may involve glycinergic stimulation of a primed N-methyl-d-aspartate receptor","volume":"29","author":"Deutsch","year":"2006","journal-title":"Clinical Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0150","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","article-title":"Epilepsy","volume":"4","author":"Devinsky","year":"2018","journal-title":"Nature Reviews. Disease Primers"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0155","series-title":"Jasper\u2019s basic mechanisms of the epilepsies","first-page":"611","article-title":"Neuroinflammation in epilepsy: Cellular and molecular mechanisms","author":"Dingledine","year":"2024"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0160","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1182\/blood-2023-174293","article-title":"Preclinical studies of the GlyT1 inhibitor Bitopertin in diamond-Blackfan Anemia","volume":"142","author":"Doty","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0165","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1038\/npp.2011.295","article-title":"Glycine transporter inhibitor attenuates the psychotomimetic effects of ketamine in healthy males: Preliminary evidence","volume":"37","author":"D\u2019Souza","year":"2012","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0170","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1038\/nature14853","article-title":"Glycine receptor mechanism elucidated by electron cryo-microscopy","volume":"526","author":"Du","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0175","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.cmet.2016.08.009","article-title":"One-carbon metabolism in health and disease","volume":"25","author":"Ducker","year":"2017","journal-title":"Cell Metabolism"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0180","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1111\/j.1460-9568.2009.06903.x","article-title":"Splice-specific roles of glycine receptor alpha3 in the hippocampus","volume":"30","author":"Eichler","year":"2009","journal-title":"European Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0185","doi-asserted-by":"crossref","first-page":"2848","DOI":"10.1111\/j.1582-4934.2008.00357.x","article-title":"Glycinergic tonic inhibition of hippocampal neurons with depolarizing GABAergic transmission elicits histopathological signs of temporal lobe epilepsy","volume":"12","author":"Eichler","year":"2008","journal-title":"Journal of Cellular and Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0190","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.yebeh.2018.09.034","article-title":"Follow-up of patients with epilepsy harboring antiglycine receptor antibodies","volume":"92","author":"Ekizoglu","year":"2019","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0195","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1055\/s-0040-1718719","article-title":"Epilepsy-definition, classification, pathophysiology, and epidemiology","volume":"40","author":"Falco-Walter","year":"2020","journal-title":"Seminars in Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0200","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s11920-010-0122-x","article-title":"Promise and pitfalls of animal models of schizophrenia","volume":"12","author":"Feifel","year":"2010","journal-title":"Current Psychiatry Reports"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0205","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1111\/epi.12550","article-title":"ILAE official report: A practical clinical definition of epilepsy","volume":"55","author":"Fisher","year":"2014","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/S2215-0366(20)30513-7","article-title":"Efficacy and safety of the novel glycine transporter inhibitor BI 425809 once daily in patients with schizophrenia: A double-blind, randomised, placebo-controlled phase 2 study","volume":"8","author":"Fleischhacker","year":"2021","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0215","first-page":"377","article-title":"The rocking bundle: A mechanism for ion-coupled solute flux by symmetrical transporters","volume":"24","author":"Forrest","year":"2009","journal-title":"Physiology (Bethesda)"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0220","doi-asserted-by":"crossref","DOI":"10.1111\/jnc.70061","article-title":"Milestone review: Unlocking the proteomics of Glycine receptor complexes","volume":"169","author":"Fraser","year":"2025","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0225","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/0091-3057(85)90288-6","article-title":"Prevention of strychnine-induced seizures and death by the N-methylated glycine derivatives betaine, dimethylglycine and sarcosine","volume":"22","author":"Freed","year":"1985","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0230","first-page":"G856","article-title":"Molecular evidence for a glycine-gated chloride channel in macrophages and leukocytes","volume":"283","author":"Froh","year":"2002","journal-title":"American Journal of Physiology: Gastrointestinal and Liver Physiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0235","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.762564","article-title":"Glycinergic signaling in macrophages and its application in macrophage-associated diseases","volume":"12","author":"Gan","year":"2021","journal-title":"Frontiers in Immunology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0240","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1021\/acschemneuro.5c00039","article-title":"Effect of SSR504734, a selective glycine transporter type 1 inhibitor, on seizure thresholds, neurotransmitter levels, and inflammatory markers in mice","volume":"16","author":"Gapi\u0144ska","year":"2025","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0245","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0141221","article-title":"Repeated 6-Hz corneal stimulation progressively increases FosB\/\u0394FosB levels in the lateral amygdala and induces seizure generalization to the Hippocampus","volume":"10","author":"Giordano","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0250","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/S0896-6273(03)00672-X","article-title":"Inactivation of the glycine transporter 1 gene discloses vital role of glial glycine uptake in glycinergic inhibition","volume":"40","author":"Gomeza","year":"2003","journal-title":"Neuron"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1058488","article-title":"Regulation by Nrf2 of IL-1\u03b2-induced inflammatory and oxidative response in VSMC and its relationship with TLR4","volume":"14","author":"Gonz\u00e1lez-Carnicero","year":"2023","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0260","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1038\/nn.3934","article-title":"Animal models in epilepsy research: Legacies and new directions","volume":"18","author":"Grone","year":"2015","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0265","doi-asserted-by":"crossref","first-page":"7189","DOI":"10.1073\/pnas.89.15.7189","article-title":"Cloning, expression, and localization of a rat brain high-affinity glycine transporter","volume":"89","author":"Guastella","year":"1992","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0270","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/BF00967256","article-title":"Co-variation of free amino acids in human epileptogenic cortex","volume":"18","author":"Hamberger","year":"1993","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0275","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.2174\/092986706776360932","article-title":"Glycine transporter type-1 and its inhibitors","volume":"13","author":"Harsing","year":"2006","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0280","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1556\/APhysiol.99.2012.1.1","article-title":"Interactions between glycine transporter type 1 (GlyT-1) and some inhibitor molecules - glycine transporter type 1 and its inhibitors (review)","volume":"99","author":"Harsing","year":"2012","journal-title":"Acta Physiologica Hungarica"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0285","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.964488","article-title":"NKCC1 and KCC2: Structural insights into phospho-regulation","volume":"15","author":"Hartmann","year":"2022","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0290","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3389\/neuro.02.001.2008","article-title":"A critical role for glycine transporters in hyperexcitability disorders","volume":"1","author":"Harvey","year":"2008","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0295","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1038\/nrd3893","article-title":"Glycine transporters as novel therapeutic targets in schizophrenia, alcohol dependence and pain","volume":"12","author":"Harvey","year":"2013","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0300","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/S0028-3908(01)00043-0","article-title":"Pharmacological assessment of the role of the glycine transporter GlyT-1 in mediating high-affinity glycine uptake by rat cerebral cortex and cerebellum synaptosomes","volume":"41","author":"Herdon","year":"2001","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0305","doi-asserted-by":"crossref","first-page":"15","DOI":"10.4196\/kjpp.2013.17.1.15","article-title":"Influence of aspirin on pilocarpine-induced epilepsy in mice","volume":"17","author":"Jeong","year":"2013","journal-title":"Korean Journal of Physiology & Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0310","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.14202\/vetworld.2025.3041-3050","article-title":"Experimental models of epilepsy: A comprehensive review of mechanisms, translational relevance, and future directions","volume":"18","author":"Jiji","year":"2025","journal-title":"Vet. World."},{"key":"10.1016\/j.pharmthera.2026.109106_bb0315","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1046\/j.1471-4159.1996.67010336.x","article-title":"Developmental expression of the glycine transporters GLYT1 and GLYT2 in mouse brain","volume":"67","author":"Jursky","year":"1996","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0320","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/nrn3819","article-title":"Cation-chloride cotransporters in neuronal development, plasticity and disease","volume":"15","author":"Kaila","year":"2014","journal-title":"Nature Reviews. Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0325","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.brainres.2010.03.032","article-title":"Glycine transporter 1 (GlyT1) inhibitors exhibit anticonvulsant properties in the rat maximal electroshock threshold (MEST) test","volume":"1331","author":"Kalinichev","year":"2010","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0330","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1111\/j.1471-4159.1993.tb03283.x","article-title":"Amino acid levels in the cerebrospinal fluid of newly diagnosed epileptic patients: Effect of vigabatrin and carbamazepine monotherapies","volume":"60","author":"K\u00e4lvi\u00e4inen","year":"1993","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0335","doi-asserted-by":"crossref","first-page":"1693","DOI":"10.2147\/NDT.S50371","article-title":"Animal models of epilepsy: Use and limitations","volume":"10","author":"Kandratavicius","year":"2014","journal-title":"Neuropsychiatric Disease and Treatment"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0340","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1515\/REVNEURO.2009.20.1.13","article-title":"Glycinergic inhibition in the hippocampus","volume":"20","author":"Keck","year":"2009","journal-title":"Reviews in the Neurosciences"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0345","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1038\/s41573-024-00981-w","article-title":"New epilepsy therapies in development","volume":"23","author":"Klein","year":"2024","journal-title":"Nature Reviews. Drug Discovery"},{"issue":"Suppl. 9","key":"10.1016\/j.pharmthera.2026.109106_bb0350","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1111\/epi.12031","article-title":"The emerging role of DNA methylation in epileptogenesis","volume":"53","author":"Kobow","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0355","doi-asserted-by":"crossref","DOI":"10.1155\/2021\/9999146","article-title":"Neuroinflammation: An integrating overview of reactive neuroimmune cell interactions in health and disease","volume":"2021","author":"K\u00f6lliker-Frers","year":"2021","journal-title":"Mediators of Inflammation"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0360","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/j.bcp.2010.07.004","article-title":"Glycine transporter (GlyT1) inhibitors with reduced residence time increase prepulse inhibition without inducing hyperlocomotion in DBA\/2 mice","volume":"80","author":"Kopec","year":"2010","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0365","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1111\/j.1528-1167.2009.02397.x","article-title":"Definition of drug resistant epilepsy: Consensus proposal by the ad hoc task force of the ILAE commission on therapeutic strategies","volume":"51","author":"Kwan","year":"2010","journal-title":"Epilepsia"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0370","first-page":"23","article-title":"Glycine receptors caught between genome and proteome - functional implications of RNA editing and splicing","volume":"2","author":"Legendre","year":"2009","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0375","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.seizure.2010.12.005","article-title":"Cytokines and epilepsy","volume":"20","author":"Li","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0380","doi-asserted-by":"crossref","first-page":"S253","DOI":"10.3233\/JAD-230059","article-title":"Neuroinflammation: A common pathway in Alzheimer\u2019s disease and epilepsy","volume":"94","author":"Liew","year":"2023","journal-title":"Journal of Alzheimer\u2019s Disease"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0385","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.3389\/fneur.2019.01407","article-title":"Role of NKCC1 and KCC2 in epilepsy: From expression to function","volume":"10","author":"Liu","year":"2019","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0390","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1016\/j.brainresbull.2006.03.007","article-title":"Modulatory effects of d-serine and sarcosine on NMDA receptor-mediated neurotransmission are apparent after stress in the genetically inbred BALB\/c mouse strain","volume":"69","author":"Long","year":"2006","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0395","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1007\/978-3-319-55769-4_2","article-title":"Glycine transporters in glia cells: Structural studies","volume":"16","author":"L\u00f3pez-Corcuera","year":"2017","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0400","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1080\/09687680010028762","article-title":"Glycine neurotransmitter transporters: an update","volume":"18","author":"L\u00f3pez-Corcuera","year":"2001","journal-title":"Molecular Membrane Biology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0405","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0410","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"L\u00f6scher","year":"2016","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0415","doi-asserted-by":"crossref","first-page":"1926","DOI":"10.1007\/s11064-016-2025-7","article-title":"The search for new screening models of Pharmacoresistant epilepsy: Is induction of acute seizures in epileptic rodents a suitable approach?","volume":"42","author":"L\u00f6scher","year":"2017","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0420","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.730257","article-title":"Single-target versus multi-target drugs versus combinations of drugs with multiple targets: Preclinical and clinical evidence for the treatment or prevention of epilepsy","volume":"12","author":"L\u00f6scher","year":"2021","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0425","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40263-021-00827-8","article-title":"The pharmacology and clinical efficacy of Antiseizure medications: From bromide salts to Cenobamate and beyond","volume":"35","author":"L\u00f6scher","year":"2021","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0430","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1152\/physrev.00042.2003","article-title":"Molecular structure and function of the glycine receptor chloride channel","volume":"84","author":"Lynch","year":"2004","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0435","first-page":"395","article-title":"Animal models of schizophrenia: A critical review","volume":"26","author":"Marcotte","year":"2001","journal-title":"Journal of Psychiatry and Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0440","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1002\/cne.23510","article-title":"Distribution of neuronal KCC2a and KCC2b isoforms in mouse CNS","volume":"522","author":"Markkanen","year":"2014","journal-title":"Journal of Comparative Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0445","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.neubiorev.2020.07.025","article-title":"Neurobiology of glycine transporters: From molecules to behavior","volume":"118","author":"Marques","year":"2020","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0450","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1038\/npp.2012.212","article-title":"Glycine transporter type 1 occupancy by bitopertin: A positron emission tomography study in healthy volunteers","volume":"38","author":"Martin-Facklam","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0455","first-page":"E7179","article-title":"Glycine receptor \u03b13 and \u03b12 subunits mediate tonic and exogenous agonist-induced currents in forebrain","volume":"114","author":"McCracken","year":"2017","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0460","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41401-023-01149-9","article-title":"Neuronal K(+)-cl(\u2212) cotransporter KCC2 as a promising drug target for epilepsy treatment","volume":"45","author":"McMoneagle","year":"2024","journal-title":"Acta Pharmacologica Sinica"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0465","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1124\/mol.108.049312","article-title":"Inhibitors of GlyT1 affect glycine transport via discrete binding sites","volume":"74","author":"Mezler","year":"2008","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0470","first-page":"1863","article-title":"Cerebral cortical circuitry formation requires functional Glycine receptors","volume":"27","author":"Morelli","year":"2017","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0475","first-page":"451","article-title":"Limitations of animal epilepsy research models: Can epileptic human tissue provide translational benefit?","volume":"38","author":"Morris","year":"2021","journal-title":"Altex"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0480","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/s13318-017-0440-z","article-title":"Safety, tolerability and pharmacokinetics of Oral BI 425809, a Glycine transporter 1 inhibitor, in healthy male volunteers: A partially randomised, single-blind, placebo-controlled, first-in-human study","volume":"43","author":"Moschetti","year":"2018","journal-title":"European Journal of Drug Metabolism and Pharmacokinetics"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0485","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s40261-018-0660-2","article-title":"Multiple rising doses of Oral BI 425809, a GlyT1 inhibitor, in young and elderly healthy volunteers: A randomised, double-blind, phase I study investigating safety and pharmacokinetics","volume":"38","author":"Moschetti","year":"2018","journal-title":"Clinical Drug Investigation"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0490","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1038\/nn.2647","article-title":"Animal models of neuropsychiatric disorders","volume":"13","author":"Nestler","year":"2010","journal-title":"Nature Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0495","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1002\/glia.23519","article-title":"Blocking TNF\u03b1-driven astrocyte purinergic signaling restores normal synaptic activity during epileptogenesis","volume":"66","author":"Nikolic","year":"2018","journal-title":"Glia"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0500","doi-asserted-by":"crossref","first-page":"449","DOI":"10.21037\/atm-22-1219","article-title":"Metabonomic analysis of cerebrospinal fluid in epilepsy","volume":"10","author":"Niu","year":"2022","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0505","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/S0092-8674(00)81656-6","article-title":"DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development","volume":"99","author":"Okano","year":"1999","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0510","doi-asserted-by":"crossref","first-page":"R733","DOI":"10.1016\/j.cub.2012.07.029","article-title":"Evolution of inflammatory diseases","volume":"22","author":"Okin","year":"2012","journal-title":"Current Biology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0515","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2021.742058","article-title":"Directly and indirectly targeting the Glycine modulatory site to modulate NMDA receptor function to address unmet medical needs of patients with schizophrenia","volume":"12","author":"Pei","year":"2021","journal-title":"Frontiers in Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0520","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S0306-4522(00)00515-7","article-title":"Interleukin-6 deficiency reduces the brain inflammatory response and increases oxidative stress and neurodegeneration after kainic acid-induced seizures","volume":"102","author":"Penkowa","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0525","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.neuropharm.2008.06.016","article-title":"Neurochemical and behavioral profiling of the selective GlyT1 inhibitors ALX5407 and LY2365109 indicate a preferential action in caudal vs. cortical brain areas","volume":"55","author":"Perry","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0530","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1212\/WNL.31.7.872","article-title":"Amino acid abnormalities in epileptogenic foci","volume":"31","author":"Perry","year":"1981","journal-title":"Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0535","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/S1474-4422(07)70215-6","article-title":"Development of new antiepileptic drugs: Challenges, incentives, and recent advances","volume":"6","author":"Perucca","year":"2007","journal-title":"Lancet Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0540","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/0014-2999(91)90498-F","article-title":"Anticonvulsant drug potentiation by glycine in maximal electroshock seizures is mimicked by D-serine and antagonized by 7-chlorokynurenic acid","volume":"199","author":"Peterson","year":"1991","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0545","series-title":"Neuropharmacology methods in epilepsy research","article-title":"Electroshock","author":"Peterson","year":"1998"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0550","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0920-1211(93)90094-N","article-title":"The anticonvulsant activity of D-cycloserine is specific for tonic convulsions","volume":"15","author":"Peterson","year":"1993","journal-title":"Epilepsy Research"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0555","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252313133","article-title":"Calcium ions in the physiology and pathology of the central nervous system","volume":"25","author":"Pikor","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0560","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2023.109514","article-title":"Functional crosstalk of the glycine transporter GlyT1 and NMDA receptors","volume":"232","author":"Piniella","year":"2023","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0565","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/7355_2014_53","article-title":"GlyT-1 inhibitors: From hits to clinical candidates","volume":"13","author":"Porter","year":"2014","journal-title":"Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0570","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1152\/physrev.00025.2021","article-title":"Chloride transporters controlling neuronal excitability","volume":"103","author":"Pressey","year":"2023","journal-title":"Physiological Reviews"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0575","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1016\/j.bmcl.2006.12.063","article-title":"1,3-diaminopropan-2-ol sulfonamides as potent and selective inhibitors of the glycine transporter type 1","volume":"17","author":"Rahman","year":"2007","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0580","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1023\/B:NERE.0000010461.34920.0c","article-title":"Plasma and cerebrospinal fluid amino acids in epileptic patients","volume":"29","author":"Rainesalo","year":"2004","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0585","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1111\/j.1471-4159.2010.06802.x","article-title":"Functional 'glial' GLYT1 glycine transporters expressed in neurons","volume":"114","author":"Raiteri","year":"2010","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0590","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173582","article-title":"Evolving targets for anti-epileptic drug discovery","volume":"887","author":"Raut","year":"2020","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0595","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.neuint.2016.07.001","article-title":"Advances in understanding the functions of native GlyT1 and GlyT2 neuronal glycine transporters","volume":"99","author":"Romei","year":"2016","journal-title":"Neurochemistry International"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0600","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1111\/cts.12578","article-title":"Evaluation of pharmacokinetics and pharmacodynamics of BI 425809, a novel GlyT1 inhibitor: Translational studies","volume":"11","author":"Rosenbrock","year":"2018","journal-title":"Clinical and Translational Science"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0605","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1124\/jpet.121.001071","article-title":"Effects of the Glycine Transporter-1 inhibitor Iclepertin (BI 425809) on sensory processing, neural network function, and cognition in animal models related to schizophrenia","volume":"382","author":"Rosenbrock","year":"2022","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0610","doi-asserted-by":"crossref","DOI":"10.1016\/j.tvjl.2023.106014","article-title":"The role of neuroinflammation in canine epilepsy","volume":"298-299","author":"von R\u00fcden","year":"2023","journal-title":"Veterinary Journal"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0615","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s00424-013-1410-1","article-title":"The SLC6 transporters: Perspectives on structure, functions, regulation, and models for transporter dysfunction","volume":"466","author":"Rudnick","year":"2014","journal-title":"Pfl\u00fcgers Archiv \/ European Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0620","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.yebeh.2018.07.023","article-title":"Common psychiatric comorbidities in epilepsy: How big of a problem is it?","volume":"98","author":"Salpekar","year":"2019","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0625","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2022.848642","article-title":"Glycine receptor subtypes and their roles in nociception and chronic pain","volume":"15","author":"San Mart\u00edn","year":"2022","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0630","doi-asserted-by":"crossref","first-page":"2070","DOI":"10.1007\/s12035-022-03180-z","article-title":"DNA methylation description of Hippocampus, cortex, amygdala, and blood of drug-resistant temporal lobe epilepsy","volume":"60","author":"S\u00e1nchez-Jim\u00e9nez","year":"2023","journal-title":"Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0635","doi-asserted-by":"crossref","first-page":"e36","DOI":"10.3928\/00904481-20150203-10","article-title":"Antiepileptic drugs--a review","volume":"44","author":"Sankaraneni","year":"2015","journal-title":"Pediatric Annals"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/ijms25084161","article-title":"Neuroinflammation and epilepsy: From pathophysiology to therapies based on repurposing drugs","volume":"25","author":"Sanz","year":"2024","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0645","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.expneurol.2004.08.032","article-title":"Antiepileptogenic and anticonvulsant activity of interleukin-1 beta in amygdala-kindled rats","volume":"191","author":"Sayyah","year":"2005","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0650","doi-asserted-by":"crossref","first-page":"4574","DOI":"10.1093\/cercor\/bhv218","article-title":"Developmental expression patterns of KCC2 and functionally associated molecules in the human brain","volume":"26","author":"Sedmak","year":"2016","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0655","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1038\/s41586-021-03274-z","article-title":"Structural insights into the inhibition of glycine reuptake","volume":"591","author":"Shahsavar","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0660","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/j.neuropharm.2015.08.031","article-title":"Glycine transporter 1 is a target for the treatment of epilepsy","volume":"99","author":"Shen","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0665","doi-asserted-by":"crossref","first-page":"97","DOI":"10.3389\/fnmol.2020.00097","article-title":"Sarcosine suppresses Epileptogenesis in rats with effects on hippocampal DNA methylation","volume":"13","author":"Shen","year":"2020","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0670","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/jnc.13741","article-title":"Glycine release from astrocytes via functional reversal of GlyT1","volume":"140","author":"Shibasaki","year":"2017","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0675","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1037\/0735-7044.121.5.815","article-title":"Enhanced recognition memory following glycine transporter 1 deletion in forebrain neurons","volume":"121","author":"Singer","year":"2007","journal-title":"Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0680","doi-asserted-by":"crossref","first-page":"3771","DOI":"10.2174\/1381612821666150724100952","article-title":"Inhibition of glycine transporter 1: The yellow brick road to new schizophrenia therapy?","volume":"21","author":"Singer","year":"2015","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0685","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.neuroscience.2009.03.056","article-title":"Altered mnemonic functions and resistance to N-METHYL-d-aspartate receptor antagonism by forebrain conditional knockout of glycine transporter 1","volume":"161","author":"Singer","year":"2009","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0690","doi-asserted-by":"crossref","first-page":"4027","DOI":"10.1016\/j.bmcl.2004.05.043","article-title":"The synthesis and SAR of 2-arylsulfanyl-phenyl piperazinyl acetic acids as glyT-1 inhibitors","volume":"14","author":"Smith","year":"2004","journal-title":"Bioorganic & Medicinal Chemistry Letters"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0695","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/S1734-1140(10)70279-6","article-title":"Effects of sarcosine, a glycine transporter type 1 inhibitor, in two mouse seizure models","volume":"62","author":"Soca\u0142a","year":"2010","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0700","doi-asserted-by":"crossref","DOI":"10.1016\/j.yebeh.2024.109912","article-title":"MicroRNA-mediated regulation of neurotransmitter receptors in epilepsy: A systematic review","volume":"158","author":"Sonawane","year":"2024","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0705","doi-asserted-by":"crossref","first-page":"2366","DOI":"10.1152\/jn.00386.2005","article-title":"Glycine-gated chloride channels depress synaptic transmission in rat hippocampus","volume":"95","author":"Song","year":"2006","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0710","doi-asserted-by":"crossref","first-page":"8767","DOI":"10.3390\/nu7105427","article-title":"Supplementation of antipsychotic treatment with the amino acid sarcosine influences proton magnetic resonance spectroscopy parameters in left frontal White matter in patients with schizophrenia","volume":"7","author":"Strzelecki","year":"2015","journal-title":"Nutrients"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0715","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1007\/s11064-014-1504-y","article-title":"Role for pro-inflammatory cytokines in regulating expression of GABA transporter type 1 and 3 in specific brain regions of kainic acid-induced status epilepticus","volume":"40","author":"Su","year":"2015","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0720","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.neuroscience.2024.07.037","article-title":"Dynamic role of GlyT1 as glycine sink or source: Pharmacological implications for the gain control of NMDA receptors","volume":"578","author":"Supplisson","year":"2025","journal-title":"Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0725","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/ene.13721","article-title":"Antiglycine receptor antibody related disease: A case series and literature review","volume":"25","author":"Swayne","year":"2018","journal-title":"European Journal of Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0730","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1126\/science.1170116","article-title":"Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1","volume":"324","author":"Tahiliani","year":"2009","journal-title":"Science"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2026.109106_bb0735","first-page":"S133","article-title":"Antiseizure medication discovery: Recent and future paradigm shifts","volume":"7","author":"Talevi","year":"2022","journal-title":"Epilepsia Open"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0740","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3389\/fneur.2017.00301","article-title":"Drug-resistant epilepsy: Multiple hypotheses, few answers","volume":"8","author":"Tang","year":"2017","journal-title":"Frontiers in Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0745","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.yebeh.2008.09.004","article-title":"Stress, anxiety, depression, and epilepsy: Investigating the relationship between psychological factors and seizures","volume":"14","author":"Thapar","year":"2009","journal-title":"Epilepsy & Behavior"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0750","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/S0140-6736(18)32596-0","article-title":"Epilepsy in adults","volume":"393","author":"Thijs","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0755","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/j.biopsych.2003.09.012","article-title":"Glycine transporter I inhibitor, N-methylglycine (sarcosine), added to antipsychotics for the treatment of schizophrenia","volume":"55","author":"Tsai","year":"2004","journal-title":"Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0760","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.clinthera.2019.03.014","article-title":"Pharmacokinetics of single doses of BI 425809 in healthy Chinese and Japanese subjects: A randomized study","volume":"41","author":"Tsuda","year":"2019","journal-title":"Clinical Therapeutics"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0765","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jamapsychiatry.2014.163","article-title":"Effect of bitopertin, a glycine reuptake inhibitor, on negative symptoms of schizophrenia: A randomized, double-blind, proof-of-concept study","volume":"71","author":"Umbricht","year":"2014","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0770","doi-asserted-by":"crossref","first-page":"9","DOI":"10.3389\/neuro.02.009.2009","article-title":"Glycine and glycine receptor signalling in non-neuronal cells","volume":"2","author":"Van den Eynden","year":"2009","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0775","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1136\/jnnp-2016-313146","article-title":"Neuronal autoantibodies in mesial temporal lobe epilepsy with hippocampal sclerosis","volume":"87","author":"Vanli-Yavuz","year":"2016","journal-title":"Journal of Neurology, Neurosurgery, and Psychiatry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0780","doi-asserted-by":"crossref","first-page":"3","DOI":"10.5698\/1535-7511-14.s2.3","article-title":"Epilepsy and inflammation in the brain: Overview and pathophysiology","volume":"14","author":"Vezzani","year":"2014","journal-title":"Epilepsy Currents"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0785","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.expneurol.2011.09.033","article-title":"Epilepsy and brain inflammation","volume":"244","author":"Vezzani","year":"2013","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0790","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41582-019-0217-x","article-title":"Neuroinflammatory pathways as treatment targets and biomarkers in epilepsy","volume":"15","author":"Vezzani","year":"2019","journal-title":"Nature Reviews. Neurology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0795","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1016\/j.celrep.2018.09.065","article-title":"Sarcosine is uniquely modulated by aging and dietary restriction in rodents and humans","volume":"25","author":"Walters","year":"2018","journal-title":"Cell Reports"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0800","article-title":"TLR4-SIRT3 mechanism modulates mitochondrial and redox homeostasis and promotes EPCs recruitment and survival","volume":"2022","author":"Wang","year":"2022","journal-title":"Oxidative Medicine and Cellular Longevity"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0805","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1016\/j.cell.2024.02.026","article-title":"Transport mechanism and pharmacology of the human GlyT1","volume":"187","author":"Wei","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0810","series-title":"Neuropharmacology methods in epilepsy research","first-page":"27","article-title":"Chemoconvulsants","author":"White","year":"1998"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0815","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3371\/CSRP.4.2.4","article-title":"Neurodevelopmental animal models of schizophrenia: Role in novel drug discovery and development","volume":"4","author":"Wilson","year":"2010","journal-title":"Clinical Schizophrenia & Related Psychoses"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0820","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/0014-2999(94)90132-5","article-title":"Effect of the glycine\/NMDA receptor partial agonist, D-cycloserine, on seizure threshold and some pharmacodynamic effects of MK-801 in mice","volume":"257","author":"Wla\u017a","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0825","doi-asserted-by":"crossref","first-page":"170","DOI":"10.2174\/156802610790410974","article-title":"Recent progress in the discovery of non-sarcosine based GlyT1 inhibitors","volume":"10","author":"Wolkenberg","year":"2010","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0830","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.pneurobio.2010.04.008","article-title":"Glycine and glycine receptor signaling in hippocampal neurons: Diversity, function and regulation","volume":"91","author":"Xu","year":"2010","journal-title":"Progress in Neurobiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0835","doi-asserted-by":"crossref","first-page":"3169","DOI":"10.1523\/JNEUROSCI.5120-05.2006","article-title":"Disruption of glycine transporter 1 restricted to forebrain neurons is associated with a procognitive and antipsychotic phenotypic profile","volume":"26","author":"Yee","year":"2006","journal-title":"Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0840","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1038\/s41423-019-0223-3","article-title":"The benefits of neuroinflammation for the repair of the injured central nervous system","volume":"16","author":"Yong","year":"2019","journal-title":"Cellular & Molecular Immunology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0845","doi-asserted-by":"crossref","first-page":"810","DOI":"10.1002\/iub.128","article-title":"Glycine transporters and synaptic function","volume":"60","author":"Zafra","year":"2008","journal-title":"IUBMB Life"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0850","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1007\/978-3-319-55769-4_4","article-title":"Glycine transporters and its coupling with NMDA receptors","volume":"16","author":"Zafra","year":"2017","journal-title":"Adv Neurobiol"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0855","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21228573","article-title":"Insights into potential targets for therapeutic intervention in epilepsy","volume":"21","author":"Zavala-Tecuapetla","year":"2020","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0860","doi-asserted-by":"crossref","first-page":"3207","DOI":"10.1113\/jphysiol.2009.168757","article-title":"The glycine transport inhibitor sarcosine is an NMDA receptor co-agonist that differs from glycine","volume":"587","author":"Zhang","year":"2009","journal-title":"Journal of Physiology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0865","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.neuropharm.2009.07.019","article-title":"The glycine transport inhibitor sarcosine is an inhibitory glycine receptor agonist","volume":"57","author":"Zhang","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0870","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1038\/sj.npp.1301449","article-title":"Glycine uptake regulates hippocampal network activity via glycine receptor-mediated tonic inhibition","volume":"33","author":"Zhang","year":"2008","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0875","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1248\/bpb.b15-00501","article-title":"A highly selective inhibitor of Glycine Transporter-1 elevates the threshold for maximal electroshock-induced tonic seizure in mice","volume":"39","author":"Zhao","year":"2016","journal-title":"Biological & Pharmaceutical Bulletin"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0880","first-page":"229","article-title":"L-Glycine: A novel antiinflammatory, immunomodulatory, and cytoprotective agent","volume":"6","author":"Zhong","year":"2003","journal-title":"Current Opinion in Clinical Nutrition and Metabolic Care"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0885","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1042\/BST20230122","article-title":"Structural insights into NMDA receptor pharmacology","volume":"51","author":"Zhou","year":"2023","journal-title":"Biochemical Society Transactions"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0890","article-title":"Structure and mechanism of Glycine receptor elucidated by Cryo-Electron microscopy","volume":"13","author":"Zhu","year":"2022","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0895","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1007\/s12031-011-9602-7","article-title":"Increased expression of DNA methyltransferase 1 and 3a in human temporal lobe epilepsy","volume":"46","author":"Zhu","year":"2012","journal-title":"Journal of Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2026.109106_bb0900","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000016","article-title":"Glycine receptor antibodies in 2 cases of new, adult-onset epilepsy","volume":"1","author":"Zuliani","year":"2014","journal-title":"Neurol Neuroimmunol Neuroinflamm"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001336?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725826001336?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,11]],"date-time":"2026-11-11T16:01:25Z","timestamp":1794412885000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725826001336"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":180,"alternative-id":["S0163725826001336"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109106","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Targeting glycine transporter type 1 (GlyT1) in epilepsy: Pathophysiological rationale and therapeutic perspectives","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2026.109106","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"109106"}}